Official websites use .gov
A
.gov
website belongs to an official government organization in the
United States.
Secure .gov websites use HTTPS
A
lock
(
) or
https://
means you’ve safely connected to the .gov website. Share sensitive
information only on official, secure websites.
PubMed ID:
31179500
Public Release Type:
Journal
Publication Year: 2019
Affiliation: Division of Nephrology and Hypertension, Department of Medicine, University of California San Diego, San Diego, California, USA.; Kidney Research Institute, University of Washington, Seattle, Washington, USA.; Division of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA.; Division of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA.; Division of Nephrology and Hypertension, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.; Division of Hypertension and Kidney Diseases, Rhode Island Hospital, Providence, Rhode Island, USA.; Division of Nephrology and Hypertension, Department of Medicine, University of California San Diego, San Diego, California, USA.
DOI:
https://doi.org/10.1093/ajh/hpz095
Authors:
Malhotra Rakesh, Katz Ronit, Weiner Daniel E, Levey Andrew S, Cheung Alfred K, Bostom Andrew G, Ix Joachim H
Request IDs:
21306
Studies:
Folic Acid for Vascular Outcome Reduction in Transplantation Trial
In chronic kidney disease, intensive systolic blood pressure (SBP) control reduces mortality at a cost of greater acute kidney injury risk. Kidney transplantation involves implantation of denervated kidneys and immunosuppressive medications that increase acute kidney injury risk. The optimal blood pressure (BP) target in kidney transplant recipients (KTRs) is uncertain. Prior observational studies from the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) trial demonstrate associations of lower SBP levels and reduced mortality risk, but the relationship of BP with kidney allograft function remains unknown. Thus, in FAVORIT, we investigated the relationship of SBP and diastolic blood pressure (DBP) with risk of kidney allograft failure and estimated glomerular filtration rate (eGFR) slope among stable KTRs.
